Change search
ReferencesLink to record
Permanent link

Direct link
Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Medicine and Health Sciences.
Mayo Clin, FL 32224 USA.
Mayo Clin, FL 32224 USA.
Show others and affiliations
2015 (English)In: Chemical Biology and Drug Design, ISSN 1747-0277, E-ISSN 1747-0285, Vol. 86, no 5, 1036-1048 p.Article in journal (Refereed) PublishedText
Abstract [en]

The ubiquitin-proteasome system (UPS) is increasingly recognized as a therapeutic target for the development of anticancer therapies. The success of the 20S proteasome core particle (20S CP) inhibitor bortezomib in the clinical management of multiple myeloma has raised the possibility of identifying other UPS components for therapeutic intervention. We previously identified the small molecule b-AP15 as an inhibitor of 19S proteasome deubiquitinase (DUB) activity. Building upon our previous data, we performed a structure-activity relationship (SAR) study on b-AP15 and identified VLX1570 as an analog with promising properties, including enhanced potency and improved solubility in aqueous solution. In silico modeling was consistent with interaction of VLX1570 with key cysteine residues located at the active sites of the proteasome DUBs USP14 and UCHL5. VLX1570 was found to inhibit proteasome deubiquitinase activity in vitro in a manner consistent with competitive inhibition. Furthermore, using active-site-directed probes, VLX1570 also inhibited proteasome DUB activity in exposed cells. Importantly, VLX1570 did not show inhibitory activity on a panel of recombinant non-proteasome DUBs, on recombinant kinases, or on caspase-3 activity, suggesting that VLX1570 is not an overtly reactive general enzyme inhibitor. Taken together, our data shows the chemical and biological properties of VLX1570 as an optimized proteasome DUB inhibitor.

Place, publisher, year, edition, pages
WILEY-BLACKWELL , 2015. Vol. 86, no 5, 1036-1048 p.
Keyword [en]
chalcone; deubiquitinase; in silico modeling; inhibitor; lead optimization; proteasome
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-123527DOI: 10.1111/cbdd.12571ISI: 000365404100009PubMedID: 25854145OAI: diva2:886254

Funding Agencies|University of Iowa/Mayo Clinic Lymphoma SPORE Developmental Research program [P50 CA097274]; Daniel Foundation of Alabama

Available from: 2015-12-22 Created: 2015-12-21 Last updated: 2016-01-13

Open Access in DiVA

fulltext(1614 kB)10 downloads
File information
File name FULLTEXT01.pdfFile size 1614 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wang, XinD´arcy, PadraigLinder, Stig
By organisation
Division of Drug ResearchFaculty of Medicine and Health Sciences
In the same journal
Chemical Biology and Drug Design
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 10 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 61 hits
ReferencesLink to record
Permanent link

Direct link